Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FG-3180
- Development stage
- Phase 1
- Lead developer
- FibroGen
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
FG-3180 is a CD46-targeted positron emission tomography (PET) imaging agent developed for the diagnosis of solid tumors. It is composed of a radiolabeled antibody targeting CD46, enabling enhanced PET imaging to detect and assess tumors expressing this antigen. The drug is intended as a diagnostic radiopharmaceutical to aid in patient selection and monitoring in oncology, particularly prostate cancer. It is being developed by Fortis Therapeutics and FibroGen. The mechanism of action involves enhancing PET imaging through specific binding to CD46 on tumor cells.
- Other names
- 89Zr-DFO-YS5FG-3180FG3180FG 3180
02
Targets
CD46 (CD46 Molecule)
Beyond the preview
Go deeper on FG-3180.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FG-3180.